Rimegepant 75 mg Provides Early and Sustained Relief of Migraine with a Single Oral Dose: Results from 3 Phase 3 Clinical Trials

book_2 Source: AHSAM 2020 - Oral session Published on September 11, 2020
calendar_today Published on Medfyle: July 2020
import_contacts 7 min
headphones 3 min

In this medfyle

Expert commentary by Stephanie J. Nahas, MD, MSEd, FAHS, FAAN

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Read more arrow_downward Hide arrow_upward

This is a highlights summary of an oral session given at the AHSAM 2020 Virtual Annual Scientific Meeting and presented by:

Jelena Pavlovic, MD, PhD
Associate Professor Albert Einstein College of Medicine, Montefiore Headache Center
Bronx, New York

The content is produced by Infomedica, the official reporting partner of ASHAM 2020 Virtual Annual Scientific Meeting. The summary text was drafted by Goldcrest Medical Writing, reviewed by Marco Vercellino, MD, an independent external expert, and approved by Jessica Ailani, MD, FAHS and Mark J. Burish, MD, PhD, the scientific editors of the program.

The presenting authors of the original session had no part in the creation of this conference highlights summary.

In addition, an expert commentary on the topic has been provided by:

Stephanie J. Nahas, MD, MSEd, FAHS, FAAN
Associate Professor of Neurology

About the Expert
Read more arrow_downward Hide arrow_upward

Stephanie J. Nahas, MD, MSEd, FAHS, FAAN
Associate Professor of Neurology

Stephanie Nahas achieved her undergraduate degree in biology (cum laude) at Harvard in 1995. She then went to Rush Medical College where, after a brief detour to obtain a Masters degree in instructional technology from the University of Southern California in 1998, she earned her MD in 2001. She completed internship at Rush followed by neurology residency then fellowship in headache medicine at Thomas Jefferson University Hospital. In January 2007, after 1.5 years of fellowship training, she joined faculty and became the Fellowship Program Director at the Headache Center of Thomas Jefferson University. She is a dedicated advocate for the field, having attended 12 Headache on the Hill events in Washington, DC since 2007, and is immediate past Vice President of the Alliance for Headache Disorders Advocacy (February 2018 – February 2020). Dr. Nahas serves as Section Editor for Current Pain and Headache Reports, is Co-Chair of the “First Contacts: Headache Education in Primary Care” Committee of the American Headache Society, and also serves on the Education Committee and Scottsdale Program Committee for the American Headache Society. In August 2020, she was elected as the first President of the Asia Pacific Headache Society.

Read more arrow_downward Hide arrow_upward

1. Lipton RB, et al. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. NEJM 2019;381:142-49.

2. Croop R, et al. Efficacy, Safety, and Tolerability of Rimegepant Orally Disintegrating Tablet for the Acute Treatment of Migraine: A Randomised, Phase 3, Double-Blind, Placebo-Controlled Trial. Lancet 2019;394:737-745.